Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2018-A01332-53 | Other Identifier | ID-RCB |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| The Lymphoma Academic Research Organisation | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
REALYSA cohort is a population-based epidemiological platform in real-life for lymphomas designed to enrich prognostic data, by integrating together epidemiological, clinical and biological data.
REALYSA is a platform perfectly set up to
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| All enrolled patients | All patient who signed the consent form for participation to the study |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Real-life epidemiological platform of lymphoma in France | Other | The REALYSA database will be described with the following characteristics:
|
| Measure | Description | Time Frame |
|---|---|---|
| Progression-Free Survival (PFS) | 5 years |
| Measure | Description | Time Frame |
|---|---|---|
| Number of patients included per month in total and according to subtype of lymphoma | 5 years | |
| Number of patients in each region in total and according to subtype of lymphoma | 9 years | |
| Measure | Description | Time Frame |
|---|---|---|
| Representativeness of the included population | Study population must show a good representativeness of the source population regarding demographic or diseases characteristics, to be able to generalize our results. Indeed, the representativeness of the study population can only be evaluated in areas covered by population-based cancer registries (PBCR) by comparing cases included in the REALYSA project to incident lymphoma cases registered in the general population (PBCR of the FRANCIM network). |
Inclusion Criteria:
Exclusion Criteria:
Anti-lymphoma treatment already received (except pre-phase: typically corticosteroids, vincristine, cyclophosphamide, etoposide, alone or in combination)
Documented HIV infection
Any other lymphoma subtype not included in the list in Appendix 1. Of note, are excluded:
Not provided
Not provided
Not provided
Patients diagnosed with lymphoma in the last 6 months.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Hervé Ghesquières, MD | Contact | 04 78 86 43 40 | +33 | herve.ghesquieres@chu-lyon.fr |
| Alain Monnereau, MD | Contact | 05 56 33 33 33 | +33 | A.Monnereau@bordeaux.unicancer.fr |
| Name | Affiliation | Role |
|---|---|---|
| Hervé Ghesquières, MD | Hospices Civils de Lyon | Study Director |
| Alain Monnereau, MD | Université de Bordeaux : Inserm | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Unité d'Hématologie Clinique, CH D'ARRAS | Recruiting | Arras | 62022 | France |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 37874913 | Derived | Ghesquieres H, Cherblanc F, Belot A, Micon S, Bouabdallah KK, Esnault C, Fornecker LM, Thokagevistk K, Bonjour M, Bijou F, Haioun C, Morineau N, Ysebaert L, Damaj G, Tessoulin B, Guidez S, Morschhauser F, Thieblemont C, Chauchet A, Gressin R, Jardin F, Fruchart C, Laboure G, Fouillet L, Lionne-Huyghe P, Bonnet A, Lebras L, Amorim S, Leyronnas C, Olivier G, Guieze R, Houot R, Launay V, Drenou B, Fitoussi O, Detourmignies L, Abraham J, Soussain C, Lachenal F, Pica GM, Fogarty P, Cony-Makhoul P, Bernier A, Le Guyader-Peyrou S, Monnereau A, Boissard F, Rossi C, Camus V. Challenges for quality and utilization of real-world data for diffuse large B-cell lymphoma in REALYSA, a LYSA cohort. Blood Adv. 2024 Jan 23;8(2):296-308. doi: 10.1182/bloodadvances.2023010798. | |
| 33653294 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Progression-Free Survival (PFS) |
| 9 years |
| Event-Free Survival (EFS) | 5 years |
| Event-Free Survival (EFS) | 9 years |
| Overall Survival (OS) | 5 years |
| Overall Survival (OS) | 9 years |
| Net Survival | 5 years |
| Net Survival | 9 years |
| Response rate | 5 years |
| Response rate | 9 years |
| Duration of response | 5 years |
| Duration of response | 9 years |
| Time to Next Anti-Lymphoma Treatment (TTNLT) | 5 years |
| Time to Next Anti-Lymphoma Treatment (TTNLT) | 9 years |
| Duration of Survival after progression | 5 years |
| Duration of Survival after progression | 9 years |
| Frequency of Lymphoma transformations | 5 years |
| Frequency of Lymphoma transformations | 9 years |
| Frequency of Second cancers | 5 years |
| Frequency of Second cancers | 9 years |
| Frequency of other chronic disease | 5 years |
| Frequency of other chronic disease | 9 years |
| Number of exposure factors | Baseline |
| Number of comorbidities | Baseline |
| 5 years |
| Representativeness of the included population | Study population must show a good representativeness of the source population regarding demographic or diseases characteristics, to be able to generalize our results. Indeed, the representativeness of the study population can only be evaluated in areas covered by population-based cancer registries (PBCR) by comparing cases included in the REALYSA project to incident lymphoma cases registered in the general population (PBCR of the FRANCIM network). | 9 years |
| Service d'Hématologie, CHU Jean Minjoz | Recruiting | Besançon | 25030 | France |
|
| Service d'Onco-radiolothérapie, Polyclinique Bordeaux Nord Aquitaine | Recruiting | Bordeaux | 33300 | France |
|
| Institut Bergonié | Recruiting | Bordeaux | France |
|
| Centre Hospitalier Pierre Oudot | Recruiting | Bourgoin | 38302 | France |
|
| Service d'Hématologie, Institut d'Hématologie de Basse Normandie | Recruiting | Caen | 14000 | France |
|
| METROPOLE SAVOIE - SITE CHAMBERY, place Lucien Biset, | Recruiting | Chambéry | 73000 | France |
|
| Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Estaing, CHU de Clermont-Ferrand | Recruiting | Clermont-Ferrand | 63000 | France |
|
| Unité Hémopathies Lymphoïdes, Hôpital Henri Mondor | Recruiting | Créteil | 94010 | France |
|
| CHU Francois MITTERRAND | Recruiting | Dijon | France |
|
| Service Hématologie, Centre Hospitalier de Dunkerque | Recruiting | Dunkirk | 59140 | France |
|
| Service Oncologie médicale, Groupe Hospitalier Mutualiste de Grenoble, Institut Daniel Hollard, | Recruiting | Grenoble | 38028 | France |
|
| CHD Vendée | Recruiting | La Roche-sur-Yon | France |
|
| Service d'Hématologie Clinique, Centre Hospitalier Universitaire Michallon | Recruiting | La Tronche | 38700 | France |
|
| Clinique Victor Hugo | Recruiting | Le Mans | 72000 | France |
|
| Centre hospitalier Libourne | Recruiting | Libourne | 33500 | France |
|
| Service Oncologie médicale, HOPITAL SAINT VINCENT-DE-PAUL | Recruiting | Lille | 59020 | France |
|
| Service des maladies du sang, Hôpital Claude Huriez, CHRU de Lille | Recruiting | Lille | 59037 | France |
|
| Service Hématologie Clinique et Thérapie Cellulaire, CHU DE LIMOGES - HOPITAL DUPUYTREN, | Recruiting | Limoges | 87042 | France |
|
| Département d'Hématologie et Oncologie, Centre Léon Bérard | Recruiting | Lyon | 69008 | France |
|
| Département d'Hématologie Clinique, Hôpital Saint-Eloi, | Recruiting | Montpellier | 34295 | France |
|
| Service Hématologie, GH REGION MULHOUSE ET SUD ALSACE - HOPITAL EMILE MULLER, | Recruiting | Mulhouse | 68070 | France |
|
| Service d'Hématologie clinique, Centre Hospitalier Universitaire de Nantes | Recruiting | Nantes | 44093 | France |
|
| Centre Hospitalier de Niort | Recruiting | Niort | 79021 | France |
|
| Service Hématologie, Hôpital St Louis | Recruiting | Paris | 75475 | France |
|
| CHU Haut-Lévêque | Recruiting | Pessac | France |
|
| Centre Hospitalier Lyon Sud | Recruiting | Pierre-Bénite | France |
|
| Service d'Hématologie et Thérapie Cellulaire, Centre Hospitalier Universitaire de Poitiers | Recruiting | Poitiers | 86021 | France |
|
| Hématologie Clinique, CHU PONTCHAILLOU | Recruiting | Rennes | 35033 | France |
|
| Service Hématologie, Centre Hospitalier de Roubaix - Hôpital Victor Provo | Recruiting | Roubaix | 59056 | France |
|
| Service Hématologie, UNIVERSITE DE ROUEN, CENTRE HENRI BECQUEREL | Recruiting | Rouen | 76038 | France |
|
| Service Hématologie, CH YVES LE FOLL | Recruiting | Saint-Brieuc | 22027 | France |
|
| Service Hématologie, Institut Curie - Hôpital René HUGUENIN | Recruiting | Saint-Cloud | 92210 | France |
|
| Département d'Hématologie Clinique et Thérapie Cellulaire, Institut de Cancérologie Lucien Neuwirth | Recruiting | Saint-Priest-en-Jarez | 42270 | France |
|
| Hôpitaux Universitaires de Strasbourg | Recruiting | Strasbourg | France |
|
| Institut Universitaire du Cancer | Recruiting | Toulouse | France |
|
| Hématologie Clinique, CH DE BRETAGNE ATLANTIQUE | Recruiting | Vannes | 56017 | France |
|
| Derived |
| Ghesquieres H, Rossi C, Cherblanc F, Le Guyader-Peyrou S, Bijou F, Sujobert P, Fabbro-Peray P, Bernier A, Belot A, Chartier L, Fornecker LM, Baldi I, Bouabdallah K, Laurent C, Oberic L, Morineau N, Le Gouill S, Morschhauser F, Haioun C, Damaj G, Guidez S, Laboure G, Fitoussi O, Lebras L, Gressin R, Salles G, Ysebaert L, Monnereau A. A French multicentric prospective prognostic cohort with epidemiological, clinical, biological and treatment information to improve knowledge on lymphoma patients: study protocol of the "REal world dAta in LYmphoma and survival in adults" (REALYSA) cohort. BMC Public Health. 2021 Mar 2;21(1):432. doi: 10.1186/s12889-021-10433-4. |
| ID | Term |
|---|---|
| D008224 | Lymphoma, Follicular |
| D020522 | Lymphoma, Mantle-Cell |
| D018442 | Lymphoma, B-Cell, Marginal Zone |
| D016399 | Lymphoma, T-Cell |
| D006689 | Hodgkin Disease |
| D002051 | Burkitt Lymphoma |
| D008223 | Lymphoma |
| ID | Term |
|---|---|
| D008228 | Lymphoma, Non-Hodgkin |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D008232 | Lymphoproliferative Disorders |
| D008206 | Lymphatic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D007160 | Immunoproliferative Disorders |
| D007154 | Immune System Diseases |
| D016393 | Lymphoma, B-Cell |
| D020031 | Epstein-Barr Virus Infections |
| D006566 | Herpesviridae Infections |
| D004266 | DNA Virus Infections |
| D014777 | Virus Diseases |
| D007239 | Infections |
| D014412 | Tumor Virus Infections |
Not provided
Not provided